BACKGROUND: Because sudden cardiac death increases with age, implantable
cardioverter-defibrillators (ICDs) might greatly benefit the elderly. However, elderly patients …

This article addresses the feasibility and safety of ICD therapy in patients> 80 years of age.
Recent trials have expanded the indication for ICD implantation to include an increasing …

Implantable cardioverter–defibrillator (ICD) therapy decreases arrhythmic and all-cause
mortality in patients at high risk of sudden death. However, its clinical benefit in elderly …

Background—The benefit of implantable cardioverter-defibrillators (ICDs) among elderly
patients is controversial and may be attenuated by nonarrhythmic death. We examined the …

Aims The implantable defibrillator (ICD) reduces arrhythmic and all-cause mortality in
patients with a history of life-threatening ventricular arrhythmias. However, its effectiveness …

Background Elderly patients are underrepresented in clinical trials of device therapy.
Objective To provide real-world data regarding outcomes associated with device-based …

Introduction: Implantable cardioverter-defibrillator (ICD) therapy has been shown to improve
survival in patients with structural heart disease and at high risk for life threatening …

BACKGROUND: More than 80% of sudden cardiac deaths (SCDs) occur in patients≥ 65
years old; the cost-effectiveness of implantable cardioverter defibrillator (ICD) therapy in …

Aims of the Study: To examine the patterns of use, complication rates, and survival in elderly
recipients of implantable cardioverter defibrillators (ICD). Methods and Results: We followed …

Despite the increasingly high rate of implantation of cardioverter-defibrillators (ICD) in
elderly patients, data supporting their clinical and cost-effectiveness in this age stratum are …